View source for Template:Estrogen dosages for menopausal hormone therapy

{| class="wikitable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="text-align:left; margin-left:auto; margin-right:auto; border:none;"
|+ class="nowrap" | {{Navbar|Estrogen dosages for menopausal hormone therapy|mini=y}} <noinclude>[[Chemistry:Estrogen (medication)|Estrogen]]</noinclude><includeonly>Estrogen</includeonly> dosages for <noinclude>[[menopausal hormone therapy]]</noinclude><includeonly>menopausal hormone therapy</includeonly>
|-
! Route/form !! Estrogen !! Low !! Standard !! High
|-
| rowspan="8" | [[Medicine:Oral administration|Oral]] || {{No selflink|Estradiol (medication)|Estradiol}} || 0.5–1 mg/day || 1–2 mg/day || 2–4 mg/day
|-
| {{No selflink|Estradiol valerate}} || 0.5–1 mg/day || 1–2 mg/day || 2–4 mg/day
|-
| {{No selflink|Estradiol acetate}} || 0.45–0.9 mg/day || 0.9–1.8 mg/day || 1.8–3.6 mg/day
|-
| {{No selflink|Conjugated estrogens}} || 0.3–0.45 mg/day || 0.625 mg/day || 0.9–1.25 mg/day
|-
| {{No selflink|Esterified estrogens}} || 0.3–0.45 mg/day || 0.625 mg/day || 0.9–1.25 mg/day
|-
| {{No selflink|Estropipate}} || 0.75 mg/day || 1.5 mg/day || 3 mg/day
|-
| {{No selflink|Estriol (medication)|Estriol}} || 1–2 mg/day || 2–4 mg/day || 4–8 mg/day
|-
| {{No selflink|Ethinylestradiol}}<sup>a</sup> || 2.5 μg/day || 5–15 μg/day || –
|-
| [[Medicine:Nasal spray|Nasal spray]] || {{No selflink|Estradiol (medication)|Estradiol}} || 150 μg/day || 300 μg/day || 600 μg/day
|-
| [[Medicine:Transdermal patch|Transdermal patch]] || {{No selflink|Estradiol (medication)|Estradiol}} || 25 μg/day<sup>b</sup> || 50 μg/day<sup>b</sup> || 100 μg/day<sup>b</sup>
|-
| [[Transdermal gel]] || {{No selflink|Estradiol (medication)|Estradiol}} || 0.5 mg/day || 1–1.5 mg/day || 2–3 mg/day
|-
| rowspan="2" | [[Vaginal administration|Vaginal]] || {{No selflink|Estradiol (medication)|Estradiol}} || 25 μg/day || – || –
|-
| {{No selflink|Estriol (medication)|Estriol}} || 30 μg/day || 0.5 mg 2x/week || 0.5 mg/day
|-
| rowspan="3" | {{abbrlink|IM|Intramuscular}} or [[Medicine:Subcutaneous injection|{{abbr|SC|subcutaneous}} injection]] || {{No selflink|Estradiol valerate}} || – || – || 4 mg 1x/4 weeks
|-
| {{No selflink|Estradiol cypionate}} || 1 mg 1x/3–4 weeks || 3 mg 1x/3–4 weeks || 5 mg 1x/3–4 weeks
|-
| {{No selflink|Estradiol benzoate}} || 0.5 mg 1x/week || 1 mg 1x/week || 1.5 mg 1x/week
|-
| [[Medicine:Subcutaneous implant|{{abbr|SC|Subcutaneous}} implant]] || {{No selflink|Estradiol (medication)|Estradiol}} || 25 mg 1x/6 months || 50 mg 1x/6 months || 100 mg 1x/6 months
|- class="sortbottom"
| colspan="8" style="width: 1px; background-color:#eaecf0; text-align: center;" | '''Footnotes:''' <sup>a</sup> = No longer used or recommended, due to health concerns. <sup>b</sup> = As a single patch applied once or twice per week (worn for 3–4 days or 7 days), depending on the formulation. '''Note:''' Dosages are not necessarily equivalent. '''Sources:''' <noinclude><ref name="pmid16112947">{{cite journal | vauthors = Kuhl H | title = Pharmacology of estrogens and progestogens: influence of different routes of administration | journal = Climacteric | volume = 8 Suppl 1 | issue = | pages = 3–63 | year = 2005 | pmid = 16112947 | doi = 10.1080/13697130500148875 | url = http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf}}</ref><ref name="KuhlWiegratz2008">{{cite book|last1=Kuhl|first1=Herbert|last2=Wiegratz|first2=Inka|title=Klimakterium, Postmenopause und Hormonsubstitution|trans-title=Climacteric, Postmenopause and Hormone Replacement|edition=4|url=https://www.amazon.de/Klimakterium-Postmenopause-Hormonsubstitution-Herbert-Kuhl/dp/3837420434/|date=1 January 2008|language=German|publisher=UNI-MED-Verlag|isbn=978-3-83742-043-2|page=188}}</ref><ref name="WiegratzKuhl2007">{{cite journal|last1=Wiegratz|first1=I.|last2=Kuhl|first2=H.|title=Praxis der Hormontherapie in der Peri- und Postmenopause|trans-title=Practice of hormone therapy in the peri- and postmenopause|journal=Gynäkologische Endokrinologie|volume=5|issue=3|year=2007|pages=141–149|issn=1610-2894|doi=10.1007/s10304-007-0194-9}}</ref><ref name="pmid18365854">{{cite journal | vauthors = Birkhäuser MH, Panay N, Archer DF, Barlow D, Burger H, Gambacciani M, Goldstein S, Pinkerton JA, Sturdee DW | title = Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause | journal = Climacteric | volume = 11 | issue = 2 | pages = 108–23 | date = April 2008 | pmid = 18365854 | doi = 10.1080/13697130801983921 | url = }}</ref><ref name="Borgelt2010_">{{cite book|author=Laura Marie Borgelt|title=Women's Health Across the Lifespan: A Pharmacotherapeutic Approach|url=https://books.google.com/books?id=riP3pxq2jWAC&pg=PA257|year=2010|publisher=ASHP|isbn=978-1-58528-194-7|pages=257–}}</ref><ref name="DiPiroTalbert2017_">{{cite book|vauthors= DiPiro JT, Talbert RL, Yee GC,Matzke GR, Wells BG, Posey LM|title=Pharmacotherapy: A Pathophysiologic Approach, Tenth Edition|url=https://books.google.com/books?id=BwF9DQAAQBAJ|date=23 January 2017|publisher=McGraw-Hill Education|isbn=978-1-259-58749-8|page=1295}}</ref><ref name="pmid18042008">{{cite journal | vauthors = Simon JA, Snabes MC | title = Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen | journal = Expert Opin Investig Drugs | volume = 16 | issue = 12 | pages = 2005–20 | date = December 2007 | pmid = 18042008 | doi = 10.1517/13543784.16.12.2005 | url = }}</ref><ref name="FritzSperoff2012_Composition">{{cite book|author1=Marc A. Fritz|author2=Leon Speroff|title=Clinical Gynecologic Endocrinology and Infertility|url=https://books.google.com/books?id=KZLubBxJEwEC&pg=PA751|date=28 March 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-4511-4847-3|pages=751–753}}</ref><ref name="ThomasKeenan1986_">{{cite book|last1=Thomas|first1=John A.|last2=Keenan|first2=Edward J.|chapter=Estrogens and Antiestrogenic Drugs|pages=135–165|doi=10.1007/978-1-4684-5036-1_7|title=Principles of Endocrine Pharmacology|url=https://books.google.com/books?id=mTagBQAAQBAJ&pg=PA150|date=6 December 1986|publisher=Springer Science & Business Media|isbn=978-1-4684-5036-1}}</ref><ref name="Ruggiero2002">{{cite journal|last1=Ruggiero|first1=R|title=Estrogen: physiology, pharmacology, and formulations for replacement therapy|journal=Journal of Midwifery & Women's Health|volume=47|issue=3|year=2002|pages=130–138|issn=15269523|doi=10.1016/S1526-9523(02)00233-7}}</ref><ref name="Depo-Estradiol-Label 2005">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/085470s015lbl.pdf]</ref><ref name="BruntonLazo2005_">{{cite book|author1=Laurence Brunton|author2=John Lazo|author3=Keith Parker|title=Goodman & Gilman's The Pharmacological Basis of Therapeutics, Eleventh Edition|url=https://books.google.com/books?id=PtWdBgnQdjMC|date=13 September 2005|publisher=McGraw Hill Professional|isbn=978-0-07-160891-6|page=1553|quote=These preparations differ widely in their oral potencies; e.g., a dose of 0.625 mg of conjugated estrogens generally is considered equivalent to 5 to 10 μg of ethinyl estradiol.}}</ref><ref name="pmid29693907">{{cite journal|last1=Kutlesic|first1=Ranko|last2=Popovic|first2=Jasmina|last3=Stefanovic|first3=Milan|last4=Vukomanovic|first4=Predrag|last5=Andric|first5=Aleksandra|last6=Milosevic|first6=Jelena|title=Menopausal hormone therapy: Benefits and different forms|journal=Medicinski pregled|volume=69|issue=7-8|year=2016|pages=247–254|issn=0025-8105|pmid=29693907|doi=10.2298/MPNS1608247K}}</ref></noinclude><includeonly>See template.</includeonly>
|}<!--

--><noinclude>{{Documentation|content=
==See also==
* [[Template:Estrogen dosages for breast and prostate cancer]]
* [[Template:Medications and dosages used in hormone therapy for transgender women]]

==References==
{{Reflist}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>